PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated?

SIMPLE SUMMARY: The recent approval of the drug Pembrolizumab for patients with the triple-negative subtype of breast cancer highlights the search for new markers to indicate the treatment. Due to their broad regulatory role and tissue specificity, lncRNA molecules can rise as biomarkers. Therefore,...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathias, Carolina, Kozak, Vanessa Nascimento, Magno, Jessica Maria, Baal, Suelen Cristina Soares, dos Santos, Victor Henrique Apolonio, Ribeiro, Enilze Maria de Souza Fonseca, Gradia, Daniela Fiori, Castro, Mauro Antonio Alves, Carvalho de Oliveira, Jaqueline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572024/
https://www.ncbi.nlm.nih.gov/pubmed/37835376
http://dx.doi.org/10.3390/cancers15194682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572024/
https://www.ncbi.nlm.nih.gov/pubmed/37835376
http://dx.doi.org/10.3390/cancers15194682

Ejemplares similares